MX2022015419A - Tratamiento de enfermedades caracterizadas por la sobreexpresion del receptor hepatocelular productor de eritropoyetina a2 (epha2). - Google Patents

Tratamiento de enfermedades caracterizadas por la sobreexpresion del receptor hepatocelular productor de eritropoyetina a2 (epha2).

Info

Publication number
MX2022015419A
MX2022015419A MX2022015419A MX2022015419A MX2022015419A MX 2022015419 A MX2022015419 A MX 2022015419A MX 2022015419 A MX2022015419 A MX 2022015419A MX 2022015419 A MX2022015419 A MX 2022015419A MX 2022015419 A MX2022015419 A MX 2022015419A
Authority
MX
Mexico
Prior art keywords
epha2
erythropoietin
overexpression
treatment
diseases characterized
Prior art date
Application number
MX2022015419A
Other languages
English (en)
Inventor
Michael Rigby
Gavin Bennett
Stephen Blakemore
Carly Campbell
Original Assignee
Bicycletx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bicycletx Ltd filed Critical Bicycletx Ltd
Publication of MX2022015419A publication Critical patent/MX2022015419A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un conjugado de toxina de dos ciclos BT5528, o sales farmacéuticamente aceptables de este, o composiciones farmacéuticas de este, y usos de este.
MX2022015419A 2020-06-12 2021-06-11 Tratamiento de enfermedades caracterizadas por la sobreexpresion del receptor hepatocelular productor de eritropoyetina a2 (epha2). MX2022015419A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063038279P 2020-06-12 2020-06-12
PCT/GB2021/051451 WO2021250418A1 (en) 2020-06-12 2021-06-11 Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2)

Publications (1)

Publication Number Publication Date
MX2022015419A true MX2022015419A (es) 2023-03-17

Family

ID=76641715

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015419A MX2022015419A (es) 2020-06-12 2021-06-11 Tratamiento de enfermedades caracterizadas por la sobreexpresion del receptor hepatocelular productor de eritropoyetina a2 (epha2).

Country Status (10)

Country Link
US (1) US20230233698A1 (es)
EP (1) EP4165414A1 (es)
JP (1) JP2023529214A (es)
KR (1) KR20230065231A (es)
CN (1) CN115698720A (es)
AU (1) AU2021289095A1 (es)
CA (1) CA3180095A1 (es)
IL (1) IL298868A (es)
MX (1) MX2022015419A (es)
WO (1) WO2021250418A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032678A (zh) 2017-06-26 2020-04-17 拜西克尔德有限公司 具有可检测部分的双环肽配体和其用途
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
BR112021022315A2 (pt) 2019-05-09 2021-12-28 Bicycletx Ltd Ligantes de peptídeo bicíclicos específicos para ox40
TW202110485A (zh) 2019-07-30 2021-03-16 英商拜西可泰克斯有限公司 異質雙環肽複合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918844A (zh) * 2007-06-18 2010-12-15 米迪缪尼有限公司 表达epha2和erbb2的细胞的协同治疗
EP2653543A1 (en) 2008-02-05 2013-10-23 Bicycle Therapeutics Limited Methods and Compositions
WO2016171242A1 (ja) * 2015-04-24 2016-10-27 第一三共株式会社 Ｅｐｈａ２の検出
CN108883199A (zh) * 2016-03-16 2018-11-23 梅里麦克制药股份有限公司 肝配蛋白受体a2(epha2)的纳米脂质体靶向和相关诊断
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
US20220184222A1 (en) * 2019-04-02 2022-06-16 Bicycletx Limited Bicycle toxin conjugates and uses thereof
CN114760988A (zh) * 2019-11-27 2022-07-15 拜斯科技术开发有限公司 对EphA2具有特异性的双环肽配体和其用途

Also Published As

Publication number Publication date
US20230233698A1 (en) 2023-07-27
JP2023529214A (ja) 2023-07-07
EP4165414A1 (en) 2023-04-19
AU2021289095A1 (en) 2023-01-05
WO2021250418A1 (en) 2021-12-16
CN115698720A (zh) 2023-02-03
CA3180095A1 (en) 2021-12-16
KR20230065231A (ko) 2023-05-11
IL298868A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
MX2022015419A (es) Tratamiento de enfermedades caracterizadas por la sobreexpresion del receptor hepatocelular productor de eritropoyetina a2 (epha2).
MX2022006001A (es) Ligandos de peptidos biciclicos especificos para el receptor 2 tipo a de efrina (epha2) y usos de los mismos.
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
MX2022002592A (es) Conjugado de anticuerpo-farmaco que comprende un anticuerpo contra el gen del receptor huerfano 1 similar a tirosina cinasa receptora (ror1) humano y uso para el mismo.
NZ598021A (en) Prodrugs comprising an insulin linker conjugate
MY158974A (en) Prodrugs comprising an exendin linker conjugate
MD4539C1 (ro) 4-Fenilpiridine substituite pentru tratamentul bolilor asociate cu receptorul NK-1
MX2012007410A (es) Compuestos antivirales novedosos.
MX2023001588A (es) Conjugados biciclo específicos para nectina-4 y usos de estos.
TN2011000172A1 (en) Therapeutic antiviral peptides
TW200637544A (en) Medicaments for the treatment or prevention of fibrotic diseases
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
MX2010002735A (es) Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno.
MY158809A (en) Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
JOP20210259A1 (ar) مستقبل استروجين يحلل خمير يستهدف التحلل البروتيني
MX2020007985A (es) Inhibicion del canal ionico receptor de potencial transitorio a1.
MX2009010374A (es) Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos.
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
MX2022004197A (es) Inhibidores del factor d del complemento para administracion oral.
MX2020010201A (es) Conjugado de farmaco citotoxico y forma de profarmaco de dicho conjugado.
MX2012008509A (es) Agente terapeutico o profilactic para enfermedades del tracto biliar.
MX2009007040A (es) Derivados de mononitrato de isosorbida para el tratamiento de hipertension ocular.
MX2011008627A (es) Metodos de administracion de (4ar, 10ar)-1-n-propil-1,2,3,4,4a,5,1 0,10a-octahidro-benzo[g]quinolin-6,7-diol y compuestos relacionados a traves de la mucosa oral, la mucosa nasal o la piel y composiciones farmaceuticas de los mismos.
PT1778837E (pt) Tratamento de doenças neurodegenerativas por utilização de inibidores de scd4
MX2023011297A (es) Antagonista del dominio de alfa/beta hidrolasa 6 (abhd6).